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Abstract
Background: The actin cytoskeleton plays a crucial role in supporting and regulating numerous cellular processes.
Mutations or alterations in the expression levels affecting the actin cytoskeleton system or related regulatory
mechanisms are often associated with complex diseases such as cancer. Understanding how qualitative or quantitative
changes in expression of the set of actin cytoskeleton genes are integrated to control actin dynamics and organisation is
currently a challenge and should provide insights in identifying potential targets for drug discovery. Here we report the
development of a dedicated microarray, the Actichip, containing 60-mer oligonucleotide probes for 327 genes selected
for transcriptome analysis of the human actin cytoskeleton.
Results: Genomic data and sequence analysis features were retrieved from GenBank and stored in an integrative
database called Actinome. From these data, probes were designed using a home-made program (CADO4MI) allowing
sequence refinement and improved probe specificity by combining the complementary information recovered from the
UniGene and RefSeq databases. Actichip performance was analysed by hybridisation with RNAs extracted from epithelial
MCF-7 cells and human skeletal muscle. Using thoroughly standardised procedures, we obtained microarray images with
excellent quality resulting in high data reproducibility. Actichip displayed a large dynamic range extending over three logs
with a limit of sensitivity between one and ten copies of transcript per cell. The array allowed accurate detection of small
changes in gene expression and reliable classification of samples based on the expression profiles of tissue-specific genes.
When compared to two other oligonucleotide microarray platforms, Actichip showed similar sensitivity and concordant
expression ratios. Moreover, Actichip was able to discriminate the highly similar actin isoforms whereas the two other
platforms did not.
Conclusion: Our data demonstrate that Actichip is a powerful alternative to commercial high density microarrays for
cytoskeleton gene profiling in normal or pathological samples. Actichip is available upon request.
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Background
The actin cytoskeleton is a highly dynamic network of
protein polymers extending throughout the cytoplasm. It
not only provides structural support for the cell, but also
plays a central role in key cell processes including cellular
morphogenesis, migration, division and cell communica-
tion. The actin cytoskeleton generates forces required for
membrane extension and remodelling, motor protein-
dependent cell contraction or membrane trafficking [1].
Recently, a nuclear function was identified for actin in the
organisation of chromatin and gene expression [2,3]. In
cells, the assembly and disassembly of actin filaments and
their organisation into higher-order networks is regulated
by actin-associated proteins which, in turn, are controlled
by specific signalling pathways [1,4]. The formation of
membrane-cytoskeleton specialisations not only depends
on the spatio-temporal controlled recruitment of actin-
binding proteins to cellular subdomains, but also on the
repertoire of specific sets of cytoskeleton and regulatory
proteins that cells express at a given state. In line, timely
and spatially regulated expression of cytoskeletal genes is
observed during embryonic development or terminal dif-
ferentiation of cells in adults.
The central role of the actin cytoskeleton in many essential
cellular processes makes the system susceptible to muta-
tions and alterations of gene expression level that may
cause a wide range of diseases, including muscular dystro-
phies, amyloidosis, haematological disorders and cancers
[5,6]. Many of these diseases arise from aberrant cell mor-
phogenesis, motility or communication caused by dereg-
ulation of actin dynamics or organisation. For example,
deregulated cell motility is a typical hallmark of tumour
invasion and metastasis characterising cancer malignancy.
Recent studies demonstrated that tumour cell progression
correlates with alterations of the expression profile of
actin cytoskeleton genes and genes of upstream regulatory
pathways [6-8]. Similarly, altered expression of genes
encoding cytoskeletal proteins of the contractile system of
muscle cells is observed in cardio-vascular disorders like
heart failure [9]. Therefore, cytoskeleton proteins are
potential markers for cell differentiation or disease, and
might constitute promising novel targets for therapeutic
treatments [10].
The basic set of structural and signalling protein compo-
nents of the actin cytoskeleton is now identified and
information on their biochemical or biological activities
is available. However, gaps and controversies remain on
how qualitative or quantitative changes in expression of
these proteins are integrated to control actin dynamics
and organisation in space and time. Elucidating the intri-
cate interplay between the cytoskeletal components that
cells use to build-up various cellular structures is ham-
pered by the complexity of the actin cytoskeleton system.
In this context, gene expression profiling using microar-
rays has the potential to yield a global overview on the set
of actin cytoskeleton genes expressed by a cell at a given
physiological or pathological state. The technique allows
global and parallel investigations of cellular activity, and
was used successfully to characterise the molecular basis
of a variety of complex experimental models and diseases.
Results obtained in previous profiling studies with high-
density microarrays underline the potential of this
approach for detecting changes in the repertoire of expres-
sion of the cytoskeleton genes [7,8].
Using an optimised experimental approach, we devel-
oped Actichip, a custom oligonucleotide microarray
designed to study the expression of actin cytoskeleton
genes in various cell systems. Actichip represents 327
human genes, most of them encoding proteins that bind
directly to actin and control actin dynamics or organisa-
tion, while the others are involved in signalling, cell-cell
or cell-matrix adhesion. In parallel, we developed Actin-
ome, a knowledge database that integrates information
on the target genes, including genomic data and sequence
analysis features retrieved from GenBank, and biological
function, when available. We determined the perform-
ance characteristics of Actichip and compared them with
those of two other academic or commercial oligonucle-
otide arrays. Our data indicate that Actichip exhibits solid
performance that makes it a valid platform for studying
the human transcriptome of the actin cytoskeleton.
Results
Actinome database
To facilitate the setting up of Actichip, an integrative data-
base called Actinome was implemented cataloguing
genomic data and sequence analysis features of the
human genes related to the actin cytoskeleton. We also
considered some key marker genes including adhesion
receptors, metalloproteases or extracellular matrix pro-
teins that are involved in actin-based proccesses like mor-
phogenesis or cell migration. Gene selection was
performed using the GenBank database (release
134,[11]), and was based on a combination of biological
knowledge, literature data, Gene Ontology (GO) terms
[12] and keywords in the NCBI database. Searches were
restricted to genes encoding proteins of the major func-
tional groups regulating the dynamics and organisation of
the actin cytoskeleton (Table 1). Actinome was built fol-
lowing a robust protocole as described in the "Method"
section. To date, the database compiles a set of 327 non
redundant entries and related data such as mRNA and
protein identifiers, gene names and descriptions, cyto-
bands and gene ontology annotations. Actinome is freely
available [13].BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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Oligonucleotide probe design
We decided to use long oligonucleotide probes to build
Actichip because of the numerous advantages they offer
when compared to PCR amplicons. Being fully custom-
designed, they have more uniform hybridisation charac-
teristics, they yield less non-specific hybridisation and
misidentification of gene transcripts, while exhibiting
similar sensitivity [14].
Genomic databases are still prone to modifications. While
reorganisations and changes in transcript sequences or
identifiers may account for erroneous results in microar-
ray studies, using sequence-verified probes was shown to
improve microarray measurement accuracy and consist-
ency [15,16]. Therefore, we decided mining transcript
information for probe design from several databases.
Although many programs to design oligonucleotide
probes were publicly available at the time of our study
[17-23], none of these programs allowed such an applica-
tion. Therefore, we implemented a new, freely available
program named CADO4MI (Computer-Assisted Design
of Oligonucleotides for Microarrays) [24]. As most of the
existing programs, CADO4MI uses variations of the same
algorithm and common criteria to design specific oligo-
nucleotides with optimised hybridisation features
through a multistep procedure (see "Methods"). Contrary
to these programs however, CADO4MI has the potential
to compute probe sets for the same query genes using
simultaneously two or more databases in order to select
optimal sequences. Visualisation, comparison and inte-
gration of the different probe sets are greatly facilitated by
a powerful graphical user interface. The program also
incorporates several other interesting features such as an
automatic search for missing sequences in the reference
databases and the possibility to compute and display
melting temperature (Tm) or GC content curves for indi-
vidual gene query or, alternatively, for the entire set of
sequences. These curves are helpful in selecting the appro-
priate parameters for the design of probes. CADO4MI was
used successfully in a recent study to select automatically
a set of PCR primers designed for the resequencing of
Interrupted CoDing Sequences (ICDS) [25].
We designed 60-mer oligonucleotides using the Reference
Sequence database (RefSeq) [26] and the UniGene data-
base [27] because of their complementary features. While
the former gives access to non-redundant and well-anno-
tated sequences including pseudogenes and splice vari-
ants, but is not yet exhaustive, the latter compiles
comprehensive gene-oriented clusters of sequences but
with more redundancy and incomplete or erroneous
annotations. The Actichip probe set was designed to target
each of the 327 genes defined in the Actinome database
with a single oligonucleotide without discriminating
splice variants. This was achieved for 301 entries while the
probes designed for 26 genes were shown to target more
than one sequence in at least one reference database. We
therefore selected either 2 oligonucleotides for 22 genes, 3
for 3 genes or 5 for one gene resulting in a total set of 359
oligonucleotides (Table 1). In addition, we used part of a
set of viral and bacterial probes described as having no
similarity with human transcripts [28] and sequences of
human genes reported as being housekeeping genes [29]
to generate 41 negative and 32 positive controls, respec-
tively.
Evaluation of Actichip performance
Experimental design
To evaluate the experimental performance of Actichip
microarrays, a series of repeated hybridisation experi-
Table 1: Functional groups of genes represented on the Actichip 
microarray
Gene function category Number 
of genes 
represente
d on 
Actichip
Number 
of probes
Actin 
cytoskeleton
Actins 7 8
Actin nucleators 9 14
Actin bundling (cross-
linking, severing)
52 56
Actin sequestrating 7 7
Barbed end actin 
capping
66
Pointed end capping 7 7
Filamentous actin 
stabilisation
55
Actin depolymerisation 11 11
Actin-dependent motors 42 44
Actin-related, actin-like 
proteins
16 16
Actin-binding proteins 14 14
Cytoskeletal proteins 21 21
Plasma membrane 
cortical cytoskeleton 
linkers/scaffold, signalling
52 60
Actin-based 
processes
Tissue-specific 4 5
Cell adhesion 40 49
Cancer 12 12
Signalling 10 10
DNA, transcription and 
translation factors
12 14
Total 327 359
A set of 359 long oligonucleotides (60-mer) were designed to 
represent 249 genes encoding proteins implicated in the actin 
cytoskeleton machinery or 78 genes involved in actin-based 
processes. Most of the genes (301) are represented by a unique 
probe, 22 genes by two probes, 3 genes by 3 probes and one gene by 
5 probes.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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ments, including dye swaps, were carried out with opti-
mised target labeling, hybridisation, scanning and data
analysis protocols (see "Methods"). All the procedures
were standardised to limit the impact of experimental bias
or biological variations on data. The same series of high
quality RNA samples purified from human breast adeno-
carcinoma MCF-7 cells and from human skeletal muscle
was used in our experiments. Epithelial cells and skeletal
muscle tissue were chosen because they express well-char-
acterised sets of cytoskeleton genes, and were anticipated
to give well-contrasted differential expression data when
analysed with Actichip.
Actichip image quality and data reproducibility
Microarray images exhibited good and reproducible qual-
ity parameters in both channels (Figure 1). Background
values were low and signals showed maximum dynamic
range, resulting in signal-to-background and signal-to-
noise ratios higher than 20 and 50 in each channel,
respectively. Actichip microarray images were quantified
using the Genepix Pro 6.0 software. Negative and irrele-
vant spots were removed from the dataset as described in
the "Methods" section, yielding approximately 80 % of
positive features of which 55–60 % were found to be rel-
evant.
To assess the reproducibility of Actichip data, we analysed
triplicate spots on the Actichip array (intra-array repro-
ducibility) and repeated hybridisations (technical inter-
array reproducibility). Focusing on the intrinsic perform-
ance of Actichip, we did not investigate the impact of the
hybridisation of different samples (biological inter-array
reproducibility). We calculated the standard deviation
(STD) and coefficient of variation (CV) between the nor-
malised Log2 ratios values excluding the irrelevant signals.
As shown in Table 2, the microarrays gave reproducible
results with good intra- and inter-assay STD and CV. Anal-
ysis of variance (ANOVA test) showed that the series of
normalised signal ratios was highly similar (p < 0.05). The
variability in data was also examined in the Acuity 4.0
program using the hierarchical clustering of array experi-
The Actichip microarray is composed of 6 subgrids each containing 15 × 15 spots, resulting in a total of 1350 spots Figure 1
The Actichip microarray is composed of 6 subgrids each containing 15 × 15 spots, resulting in a total of 1350 spots. Images 
were obtained following hybridisation of fluorescently-labeled samples derived from MCF-7 cells (green channel) or human 
skeletal muscle (red channel), and are representative of ten replicates.
Alexa 555 signal Alexa 647 signal Merged (647/555)
Table 2: Reproducibility of the Actichip array data
Measurements Median STD Median CV
Within array 
replicatesa
0.065 4.275 %
Inter-array repeatsb 0.103 6.228 %
(a) Intra-array reproducibility was estimated from two representative 
array experiments performed simultaneously (one standard and one 
dye-swap). Standard deviation (STD) and coefficient of variation (CV) 
of Log2 signal ratios were calculated for each measurable triplicate 
spots, and the mean values of all repeated measurements were 
computed for each array. The median of mean STDs and CVs 
obtained from the two arrays are indicated. (b) Inter-array 
reproducibility as determined from 10 arrays performed at two 
distinct time periods (5 standard and 5 dye-swap). Median STD and 
CV were calculated from the mean Log2 signal ratios obtained for 
each measurable gene over the series of arrays.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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ments with the average linkage and the Pearson correla-
tion coefficient as similarity metric. Two main clusters
were identified for correlation coefficients > 0.95 in the
dendogram resulting from this analysis, each correspond-
ing to either normal or dye-swap experiments (Figure 2).
The correlation coefficients calculated from microarray
hybridisations ranged from 0.95 to 0.99 indicating that
the assays were highly comparable. Data from assays per-
formed at different time periods were undistinguishable.
Although limited, the greatest source of variability in our
dataset was the dye exchange, indicating that a slightly
uneven incorporation of the dyes in samples occurred
during our experiments. This dye bias was compensated
through a ratio-based, global normalisation of the data.
Signal linearity and detection limit
To investigate the dynamic range of Actichip and to deter-
mine the span of this dynamic range, we used seven Ara-
bidopsis thaliana polyadenylated RNA species referred to as
spike RNAs that were in vitro synthesised from plasmids
provided by the Institute for Genomic Research [30]. The
spike RNAs were calibrated and were combined to con-
struct seven complex mixes, each mix containing six of the
seven spike RNAs in staggered concentration ranging from
10-1 to 104 copies per cell (cpc). An eighth sample was pre-
Table 3: List of the top 15 most significantly expressed genes in MCF-7 cells or in skeletal muscle as determined using the Actichip 
microarray
Gene name Gene 
Accession 
number
Score (d) Log2 expression 
ratio
Genes mainly expressed in 
skeletal muscle
Nebulette (Actin-binding Z-disk protein) NM_006393 42.93 3.81
Troponin I, fast skeletal muscle (Troponin I, fast-twitch 
isoform)
NM_003282 34.39 2.60
Huntingtin interacting protein 1 (HIP-I) NM_005338 33.55 2.59
Myosin light chain 2a NM_021223 32.80 3.26
Troponin C, skeletal muscle NM_003279 32.21 2.45
Myosin light chain 2 NM_013292 29.25 3.06
Myosin heavy chain, skeletal muscle, perinatal NM_002472 28.14 2.80
Troponin T, fast skeletal muscle isoforms NM_006757 26.04 2.71
Myosin heavy chain, cardiac muscle beta isoform NM_000257 24.94 3.12
Actin, alpha skeletal muscle (Alpha-actin 1) NM_001100 24.21 3.50
Troponin C, slow NM_003280 21.31 2.54
Nebulin NM_004543 20.17 2.78
Smoothelin NM_134269 19.50 1.32
Tropomyosin 1 alpha chain (Alpha-tropomyosin) NM_000366 18.92 1.99
Myotilin NM_006790 18.07 1.56
Genes mainly expressed in 
MCF-7 cells
Actin, cytoplasmic 2 (Gamma-actin) NM_001614 -30.24 -2.58
Elongation factor 1-beta (EF-1-beta) NM_001959 -22.14 -1.26
Actin binding protein anillin, NM_018685 -20.12 -1.13
Keratin, type I cytoskeletal 18 NM_000224 -18.78 -2.83
Ankyrin 3 (ANK-3) (Ankyrin G) NM_020987 -16.43 -2.17
Gamma-parvin NM_022141 -16.30 -1.03
Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta 
chain 2) (Beta-III spectrin)
NM_006946 -16.28 -0.84
Coronin 1B (Coronin 2) NM_020441 -15.97 -0.84
Beta-centractin (Actin-related protein 1B) (ARP1B) NM_005735 -15.79 -1.40
NB thymosin beta NM_021992 -14.92 -1.42
Coronin 2A (WD-repeat protein 2) (IR10) NM_052820 -14.39 -1.24
ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related 
protein 2/3 complex subunit 5)
NM_005717 -13.74 -1.06
Tight junction protein ZO-1 (Zonula occludens 1 protein) 
(Zona occludens 1 protein) (Tight junction protein 1)
NM_003257 -13.70 -1.28
Transcription factor 7 (T-cell-specific transcription factor 1) 
(TCF- 1) (T-cell factor 1)
NM_003202 -13.60 -0.67
Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-
associated Src substrate) (CAS) (p120(cas))
NM_001331 -13.60 -0.77
The gene list was established from our dataset through SAM analysis [64]. In SAM, the significant genes are represented on a plot by points 
displaced by a distance denoted as the score (d) from a line on which genes identified simply by chance are aligned. Log2 expression ratios were 
determined by averaging the Log2 ratios calculated from fluorescence intensities of 10 repeated hybridisations.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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pared, called the reference sample, consisting of the mix of
all spike RNAs at a concentration of 102 cpc [see Addi-
tional file 1]. Thereby, the comparison of any of the seven
RNA samples to the reference sample should theoretically
yield signal ratios ranging from 10-3-fold to 102-fold.
The graph shown in Figure 3 is a summary of a complete
hybridisation series where each curve represents the signal
ratios associated with one of the seven spike RNAs. Acti-
chip arrays displayed a near perfect dynamic range over
three logs (10–104 cpc) and the experimental Log2 ratios
match well the expected theoretical values. A wider spread
of the curves was observed for some spike RNAs indicating
that their sequences might favour hybridisation signal
accuracy. Actichip arrays accurately yielded ratios for spike
RNAs at the highest concentration (104  cpc, 102-fold
ratio) with no saturation effect. The lower limit of linear-
ity of the dynamic range was around 10 cpc, and the sig-
nals reached a bottom plateau with values close to
background noise, marking the limit of sensitivity
between 1 and 10 cpc.
Actichip reliability
To validate the reliability of Actichip data, we analysed
our dataset using the Significance Analysis of Microarrays
algorithm (SAM; [31]). SAM analysis resulted in a list of
106 and 176 genes found significantly expressed in skele-
tal muscle and MCF-7 cells, respectively (∆ = 1.85; FDR =
0 %). This list was highly enriched in marker genes char-
acteristic for either epithelial or skeletal muscle cells
(Table 3), in good agreement with the expression patterns
expected from an a priori reasoning based on biological
knowledge. Importantly, we obtained similar results
through SAM analysis using three randomly chosen exper-
iments over the entire series of assays (data not shown)
revealing that a limited number of repeats would be suffi-
cient to obtain reliable data with Actichip.
Actichip specificity
The major difficulty in designing oligonucleotide probes
for Actichip arised from the appreciable number of highly
similar genes found in the actin cytoskeleton gene family
Analysis of the reproducibility of Actichip data using a hierar- chical array clustering Figure 2
Analysis of the reproducibility of Actichip data using 
a hierarchical array clustering. The array data from ten 
replicates were clustered in the Acuity program using a hier-
archical procedure based on the average linkage method and 
Pearson correlation coefficient. The experiments are 
grouped on the resulting dendogram according to their rela-
tive degree of similarity. Experiments and dye swaps 1 to 3 
and experiments and dye swaps 4 and 5 were performed at 
two different time periods.
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Table 4: Microarray platform features
Microarray characteristics HG-U133A 2.0 (Affymetrix) Human oligonucleotide set version 2.0 
(Operon)
Probe length 25-mer 70-mer
Number of probes/probe sets > 22000 25392 including 3871 controls
Genbank
Main databases used for the design dbEST RefSeq
RefSeq UniGene (build Hs 147)
UniGene (build Hs 133)
Number of target transcripts 18400 including variants 21329 including :11530 designed from UniGene 
and RefSeq
Number of genes represented 14500 9799 designed from UniGene
Number of probes/target sequence 11 1
The table summarises the main characteristics of the two microarray platforms compared to the Actichip array. Data are from the description facts 
provided by the manufacturers.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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[32]. This is exemplified by the actin gene family which is
composed of six different isoform genes sharing not only
high sequence identity at the protein level (> 95% Id.),
but also at the nucleic acid level (> 85% Id.). For these
genes, sequence identity ranges between 91 and 99% of
the Coding Sequence (CDS), and between 57 and 83% of
the total mRNA sequence hampering the design of specific
probes.
To evaluate the specificity of the Actichip probes targeting
the actin isoforms, PCR fragments corresponding to the
target regions of the transcripts were obtained using as
template cDNA generated from Hela cell poly(A)RNA.
The purified PCR products were labeled with Alexa dyes
through direct covalent linkage and hybridised to Actichip
microarrays. As shown in Figure 4, each PCR fragment
bound to the corresponding probe. No cross-hybridisa-
tion was observed neither within the set of actin probes
nor with the other oligonucleotides included in the chip.
These results demonstrated that the oligonucleotide
probes were fully specific and indicated that the procedure
used to design the probes in CADO4MI was robust.
Cross platform comparison
To further evaluate the performance of Actichip, we com-
pared the microarray with two other well-established oli-
gonucleotide-based platforms (Table 4). We used 25-mer
oligonucleotide commercial chips (Affymetrix, human
genome U133A 2.0) and academic arrays prepared with a
70-mer oligonucleotide set (Operon, human whole
genome version 2.0). PCR-amplicon arrays were not con-
sidered to avoid bias generated by this format of probe, as
a result of either sequence errors or cross-hybridisations
[33]. Hybridisation replicates were carried out under opti-
mised and standardised protocols specific to each plat-
form using the RNA sample sets analysed with Actichip.
Microarray image analysis and data extraction were per-
formed using dedicated methods and software (see
"Methods").
Results obtained with Actichip, Affymetrix and Operon
arrays were markedly comparable (Figure 5). The percent-
age of probes found to be relevant in Genepix ranged from
53 to 55 % for MCF-7-derived RNAs whereas it varied
from 57 to 60 % for the skeletal muscle sample. Com-
Dose-response curve for the Actichip array Figure 3
Dose-response curve for the Actichip array. Each individual A. thaliana spike mix was compared directly to the reference 
mix, resulting in seven hybridisations. For each hybridisation series, the raw signals were pre-processed according to the pro-
cedure detailed in the Methods section. Array data were normalised using a median Log2 ratio-centring approach after subtrac-
tion of the local median background intensity from the median foreground intensity. The normalised Log2 ratios were averaged 
over 3 replicates, and the final ratio was computed as the exponential base 2 of this average. The abscissa indicates the spike 
RNA abundance expressed as copy per cell (cpc) in the seven spike mixes. The ordinate shows the resulting normalised inten-
sity ratios relative to the reference mix (all spikes at a concentration of 100 cpc). The data are mean values from three inde-
pendent experiments.
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pared to the Operon platform, the Actichip and Affyme-
trix arrays gave the best inter-assay reproducibility with
only 5 % of discordant data between the series of experi-
ments.
Cross-platform comparison was achieved considering
only the genes represented simultaneously on each of the
three arrays. These genes were identified by comparing the
target gene accession numbers and/or the sequences used
to design the probes as detailed in the "Methods" section.
Among the 327 genes represented on Actichip, 304 were
also targeted by the Affymetrix U133A 2.0 array and 294
by the Operon array, while 275 genes were represented
simultaneously on the three platforms. We calculated the
degree of concordance between the expression patterns as
the ratio of the number of genes simultaneously found
expressed or not expressed in our samples by two or three
of the microarray platforms to the total number of genes
commonly represented by these platforms. We found 49
% of concordant genes between Actichip and Affymetrix,
35 % between Actichip and Operon, 45 % between
Affymetrix and Operon, and 24 % when considering all
platforms. Results were comparable for the two RNA sam-
ples we analysed. The Pearson correlation coefficients (r)
calculated using the median expression Log2 ratios of the
set of concordant genes were 0.88 between Actichip and
Affymetrix, 0.63 between Actichip and Operon, and 0.67
between Affymetrix and Operon. These data indicated
that Actichip microarrays performed equally well as
Affymetrix platform while Operon arrays were less reliable
under our experimental conditions.
As a good indicator of platform specificity, we found that
the expression patterns obtained with Actichip for the
actin isoforms perfectly matched the profiles described in
the literature [34]. Cytoplasmic actin isoforms (ACTB and
ACTG1) were detected in both samples as anticipated
from their ubiquitous expression (Table 5). Two of the
four muscle actin isoforms (ATCA1 and ACTC1) were
found to be expressed in skeletal muscle but not in MCF-
7 cells while the others (ACTA2 and ACTG2) were not
detected in any sample. These expression patterns were
further confirmed by PCR using cDNAs obtained from
our samples (data not shown). Conversely, the aortic
smooth muscle (ACTA2) and gamma enteric smooth
muscle (ACTG2) actin isoforms were incorrectly identi-
Microarray platform comparison Figure 5
Microarray platform comparison. Series of expression 
profiling assays were performed using the HG-U133A 2.0 
Affymetrix GeneChip (3 replicates per RNA sample), the 
human oligonucleotide Operon set (4 replicates) and the 
Actichip arrays (10 replicates). Experiments were carried out 
using the same lots of RNAs extracted from human carci-
noma MCF-7 cell line and from human skeletal muscle. Data 
were analysed as stated in the "Methods" section resulting in 
two groups of genes : "detected" and "not detected". The 
genes found similarly expressed or not expressed in less than 
2/3 of the replicated assays were deemed "non reproduci-
ble". The histograms show the distribution of the three 
groups of genes for each platform relative to the samples. 
Results are expressed as percentages relative to the total 
number of genes simultaneously represented on each array 
platform.
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Discrimination of the actin isoforms by Actichip Figure 4
Discrimination of the actin isoforms by Actichip. PCR 
fragments corresponding to the six actin isoforms were gen-
erated from cDNA and were fluorescently labeled. The fig-
ure shows the images resulting from the specific 
hybridisations of the PCR fragments onto independent Acti-
chip arrays. ACTC1: Actin, alpha, cardiac muscle 1; ACTA2: 
Actin, alpha 2, smooth muscle, aorta; ACTG2: Actin, gamma 
2, smooth muscle, enteric; ACTB: Actin, beta; ACTG1: 
Actin, gamma 1; ACTA1 Actin, alpha 1, skeletal muscle.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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fied in the MCF-7 and skeletal muscle samples using the
Affymetrix chips. With the Operon arrays, the alpha skel-
etal muscle (ACTA1) and aortic smooth muscle (ACTA2)
actins were inaccurately detected in the MCF-7 or skeletal
muscle RNAs, respectively. In addition, Operon arrays
were unable to detect the gamma actin (ACTG1) in both
samples.
Discussion
Microarray analysis is a powerful methodology for high
throughput gene expression study which contributes to
the understanding of complex events or biological sys-
tems [35]. In the present paper we describe the design and
benchmarking of a custom-made oligonucleotide micro-
array named Actichip as a tool to study the actin cytoskel-
eton in normal or pathological situations.
We designed, produced and evaluated Actichip using opti-
mised and standardised experimental procedures and a
data evaluation pipeline we established according to the
guidelines developed by the Microarray Gene Expression
Data (MGED) Society [36]. Actichip hybridisation signals
obtained with our optimised experimental settings were
of high quality (Figure 1) leading to accurate and highly
reproducible quantification of gene expression levels
(Table 2, Figure 2). Importantly, our data indicated that
two or three replicates would be sufficient for reliable
measurements when applying the standardised proce-
dures we established. Consistent with recent studies [37-
40], our results show that a thorough standardisation of
the array and experiment design, protocols and data anal-
ysis procedures, can greatly improve microarray data qual-
ity and comparability. This is crucial for the generation of
meaningful universal gene expression index based on the
exchange and integration of data between microarray plat-
forms and laboratories.
The reliability and sensitivity of gene expression measure-
ments are other important issues when using microarrays.
In this study, we analysed two well-contrasted RNA sam-
ples, each characterised by a specific organisation of their
actin cytoskeleton and by known marker genes. Many of
these genes were found significantly expressed using Acti-
chip (Table 3), underlining the reliability of this array as a
transcriptome analysis platform and its value for the char-
acterisation and classification of biological samples based
on their transcriptome profiles. Our data further showed
that Actichip not only detects reliably qualitative gene
expression changes, but has also the potential to accu-
rately measure the amplitude of these variations (Figure
3). In addition, we determined that Actichip has the
potential to identify transcripts over a biologically mean-
ingful range including high, intermediate and rare abun-
dance classes of RNAs.
The fraction of probes on an array that yield a significant
hybridisation signal can be used as a measure of platform
sensitivity. We found a magnitude of detectable genes
ranging from 53 to 60 % with both the Actichip, Affyme-
trix and Operon microarrays (Figure 5), indicating that
the reactivity of the three platforms is similar. These
results are in good agreement with data from similar stud-
ies [16,41], and suggest that a significant fraction of
cytoskeletal genes were not or very lowly expressed in our
samples, consistent with the concept that only part of the
genome is usually expressed in a given differentiated cell
line or tissue [42].
Comparison of the expression profiles obtained from the
three platforms revealed a moderate concordance
between the datasets, the best score (49 %) being
observed between the Actichip and Affymetrix arrays.
Nevertheless, we found good correlations between the rel-
ative expression data from the different arrays when con-
sidering the subset of concordant genes. The correlation in
gene expression levels between the Actichip and Affyme-
trix arrays was particularly strong and was comparable to
those reported in similar studies for best performing
Table 5: Microarray platforms differentially discriminate the various actin isoforms
Actin isoforms Actichip Affymetrix Operon
MCF-7 Skeletal muscle MCF-7 Skeletal muscle MCF-7 Skeletal muscle
Actin, alpha 1, skeletal muscle (ACTA1) - + - + + +
Actin, alpha 2, smooth muscle, aorta (ACTA2) - - + + - +
Actin, beta (ACTB) + + + + + +
Actin, alpha, cardiac muscle 1 (ACTC1) - + - + Ø Ø
Actin, gamma 1 (ACTG1) + + + + - -
Actin, gamma 2, smooth muscle, enteric 
(ACTG2)
--+ + --
Hybridisation data were treated following the procedure specific for each platform (see "Methods") to identify genes reproducibly deemed 
expressed (+) or not expressed (-). The table summarises the expression data obtained for the different actin isoforms. Ø : Isoform not 
represented on the array.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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arrays [16,43-46]. Identifying the source of variability
between the different microarray platforms was not
straightforward since many factors could have influenced
the expression data. Indeed, microarray platforms differ
on numerous technological aspects including array for-
mat and fabrication, protocols and instrumentation, as
well as computational and statistical tools. It has been
shown that these differences could account, at least in
part, for discrepancy in the data generated by different
array technologies [33,47-50]. Although we carefully
standardised our protocols, we could not avoid some dif-
ferences in the procedures specific for each platform.
Biases in our data may partly result from dissimilarities
between the methods we used to generate and label the
samples or from differences in sensitivity between the pro-
cedures we applied to acquire and analyse the data.
We found that 7.0 % or 10.1 % of the Actichip targets were
not represented in the Affymetrix GeneChip or Operon
array, respectively [see Additional file 2]. This result is not
surprising considering that the three array platforms were
implemented using different databases or different
releases of the same database (Table 4) harbouring modi-
fications of transcript sequences, identifiers or annota-
tions. However, our data question the reliability of the
high throughput design of pangenomic probe libraries.
Focusing on a limited, easy-to-handle set of genes consti-
tutes a more careful and robust approach. In line, several
focused microarrays were recently described as powerful
alternatives to whole genome arrays to study complex bio-
logical systems [45,51,52].
On the other hand, many of the genes represented on
Actichip are highly similar and are not easy to discrimi-
nate using long oligonucleotide microarrays. When con-
sidering the actin gene family, only very limited regions of
the transcript sequences can be used for the design of
probes with convenient physical properties and specifi-
city. To design high quality probes, we developed the
CADO4MI program which allows a validation of oligonu-
cleotides by cross-comparison of their sequences with
data from several reference databases. For 219 of the 327
target genes represented on Actichip, combining informa-
tion available from the UniGene and RefSeq databases
actually allowed us to select probes with an enhanced spe-
cificity compared to those obtained using only one data-
base. The fact that Actichip was able to differentiate the
highly similar actin isoforms confirms that CADO4MI
generates highly specific probes (Figure 4, Table 5). By
contrast, some probes specific for the actin isoforms in the
Affymetrix GeneChip and in the Operon set target regions
having a high degree of similarity with several unrelated
transcripts. As a consequence, these probes may generate
false positive data due to cross-reactivity. This could
explain the erroneous detections of some actin isoforms
we observed with the Affymetrix or Operon platforms. In
line, probe sequence alignment showed that the ACTA2
Operon probe has actually the potential to cross-hybridise
with several transcripts [see Additional file 3]. By using the
probe match tool at the NetAffx analysis center, we also
found that the ACTA2 and ACTG1 probe sets from the
U133A GeneChip both perfectly match with the ACTA2
mRNA. However, our data showed that the specificity of a
probe can not be simply inferred from its design charac-
teristics. Although giving false positives in our study, the
ACTA1 Operon probe appeared to be specific as judged by
sequence alignment [see Additional file 3], and the
ACTG2 Affymetrix probe set perfectly matched with the
corresponding transcript sequence.
It is conceivable that using latest versions of commercial
arrays based on better-quality genome assembly and
annotations or on new design concept may improve
measurement accuracy and sensitivity. As an illustration,
the GeneChip Exon array recently designed by Affymetrix
with over six million probes targeting all annotated and
predicted exons in the human genome appears as a prom-
ising tool to investigate both gene expression and alterna-
tive splicing with a high resolution. Data from the
literature show that this chip may provide more accurate
gene expression measurements than traditional microar-
rays [53,54], but requires a more complex strategy for the
analysis of expression data [53,55]. Complex and time-
consuming analysis is a typical trait of high densitiy
microarrays and often represents the bottleneck of pang-
enomic expression studies. In the particular context of
studies focusing on a limited number of genes, thematic
arrays offer the possibility to overcome these limitations.
Conclusion
Altogether, our data indicate that the tools and procedures
we implemented in the course of our study constitute a
powerful approach for the design of thematic arrays. Our
data show that Actichip displays solid performance char-
acteristics that make it a valid platform for functional
genomics studies of the actin cytoskeleton in the context
of basic or clinical research. Compared to high density
microarrays, Actichip has the potential to facilitate gene
expression data analysis because of its reasonable size.
With the capacity to screen up to four samples in parallel,
Actichip also contributes to lower the cost of the analysis.
Methods
Implementation of the Actinome database
Genomic data and sequence analysis features of the genes
included in the Actichip microarray were compiled in the
Actinome database [13]. To ensure robustness of the data-
base, only mRNA sequences or complete coding cDNA
sequences (CDS) were retrieved from the NCBI database,
excluding expressed sequence tags (ESTs), sequenceBMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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tagged sites (STS), genome sequence survey (GSS), work-
ing drafts and patent sequences. Each protein was anno-
tated with high confidence through association with the
corresponding full-length transcript and protein accession
number using the RetScope platform, an in-house eukary-
otic sequence analysis platform written in Tcl/Tk. Briefly,
the protein accession numbers and sequences were first
derived from the GenBank entries found by BLASTN
homology searches from initial sequences [56]. The pro-
tein sequences were also inferred from the initial
sequences by BLASTX searches in the UniProt database
[57]. A double cross-validation was performed by assess-
ing (i) sequence identity of the BLASTX- and BLASTN-
derived proteins and (ii) their association with the same
chromosomal localisation on the human genome [58]. As
part of the RetScope platform, the GOAnno module [59]
was finally used to annotate each protein entry with the
corresponding Gene Ontology terms. GO annotations
were retrieved using high quality multiple alignment of
complete sequences computed for each protein.
Oligonucleotide probe design
Oligonucleotide probes (60-mer) were designed using the
program CADO4MI [24]. The program was written in Tcl/
Tk and was successfully tested on various operating sys-
tems such as Windows (Microsoft), Solaris (Sun),
Tru64UNIX (Compaq) and Linux (Fedora core 5, open-
SUSE 10.2). CADO4MI designed probes corresponding to
a set of query sequences using different adjustable param-
eters through the following 4 steps [see Additional file 4]
: (i) Poly(A) tails were masked in the query sequences
(>15 consecutive adenosine bases), (ii) potential cross-
hybridisations were detected using the entire sequence as
a query in the BLASTN program [56], (iii) CADO4MI per-
formed sequence analysis by moving iteratively (10 bases)
over the query sequence a sliding window with a size cor-
responding to the oligonucleotide length (60-mer). At
each iteration, sequences with no stretch of 7 or more con-
tiguous identical bases, 35 %<GC content <70 %, 87°C<
Tm < 97°C, and distance relative to 3'end ≤ 3.000 bases
were selected. The melting temperature (Tm) was evalu-
ated by the nearest-neighbor model combined with the
unified parameters defined by SantaLucia [60]. The oligo-
nucleotide specificity was checked through BLASTN by
applying the Kane's rules to the selected sequences [14].
The process resulted in a list of oligonucleotides poten-
tially targetting one or more sequences. (iv) The procedure
was completed by selecting the oligonucleotide having
the minimum number of non specific target and smallest
distance to the 3' end of the query. Being a critical point in
the design, the specificity of the probes was assessed auto-
matically by identifying the complementary target
sequences referenced in two nucleotide databases, RefSeq
(release 1) and UniGene (build 161). Probes with unique
targets in both databases were automatically selected by
CADO4MI, whereas the others were curated manually.
Actichip fabrication
Oligonucleotides were synthesized, 3'-end amino (C6)-
modified and HPLC-purified by Eurogentec (Seraing, Bel-
gium). Microarrays were manufactured by contact print-
ing using a Microgrid II microarrayer equipped with 2500
split pins (Genomic solutions, Huntingdon, United King-
dom). Oligonucleotides were spotted in triplicate onto
epoxide-coated glass slides (ArrayIt, Sunnyvale, CA, USA)
at a concentration of 25 µM in microspotting plus solu-
tion (ArrayIt). The library was printed with two array
patches per slide, each containing 32 human housekeep-
ing genes as positive controls together with 41 sequences
corresponding to viral or bacterial genes as negative con-
trols. In addition, 10 spiking controls corresponding to
Arabidopsis thaliana genes were incorporated in each array
to assess the quality of microarray hybridisations as
described below. Sequences of the corresponding 60-mer
oligonucleotides were derived from those of 70-mer
probes described elsewhere [30], and had no homology
with any known human transcript sequence as assessed by
a BLASTN analysis. Spotting was performed at a constant
temperature of 22°C with 50% controlled humidity. Fol-
lowing arraying, the slides were dried overnight and were
stored dessicated at room temperature. Actichip is availa-
ble upon request [61].
Cell culture and RNA sample preparation
Human breast adenocarcinoma MCF-7 cells (ATCC
number HTB-22) were grown to 70–80 % confluency in
Dulbecco's Modified Eagles's Medium (DMEM), 10 %
Fetal Bovine Serum, 4 mM L-Glutamine, 100 units/ml
penicillin G sodium and 100 µg/ml streptomycin sulfate.
All cell culture reagents and buffers were purchased from
Cambrex (Verviers, Belgium). Cells were washed twice
with cold phosphate buffered-saline (PBS), and total RNA
was extracted using the TRIzol reagent (Invitrogen, Merel-
beke, Belgium) according to the manufacturer's intruc-
tions. A single batch of poly(A+) RNA was prepared from
total RNA using the polyA purist kit from Ambion
(Huntingdon, United Kingdom), and was stored frozen at
-80°C in DEPC-treated water until use. Commercial
poly(A+) RNA purified from human skeletal muscle was
obtained from Ambion. RNA integrity and concentration
were evaluated by the Agilent Bioanalyser 2100 capillary
electrophoresis RNA 6000 nano assay (Agilent Biotech-
nologies, Diegem, Belgium). High quality RNAs with a
ribosomal RNA ratio greater than 1.9 and no evidence of
degradation were used in this study.BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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Gene expression profiling experiments
Two-color microarrays
Gene profiling experiments were performed using proce-
dures specific for either the Actichip microarray or the
whole human genome array manufactured by the genom-
ics laboratory at the university medical center of Utrecht
(UMCU, The Netherlands) [see Additional file 5]. Briefly,
2 µg of poly(A+) RNA were reverse-transcribed using the
Superscript II reverse transcriptase (Invitrogen) and were
labeled with Alexa fluor 555 or 647 NHS-ester dyes (Inv-
itrogen). The hybridisation was carried out at 42°C for 20
h in a Slidebooster 800 (Advalytix, Brunnthal, Germany)
with a regular microagitation of the sample. Slides were
scanned immediately after post-hybridisation washing
using a Genepix 4000B microarray fluorescence reader
(Molecular Devices, Sunnyvale, CA, USA) at a resolution
of 10 µm. A percentage of saturated pixels of 0.1 was tol-
erated during the image acquisition to allow detection of
the lowly expressed transcripts. Images were quantified
using the Genepix Pro 6.0 software (Molecular Devices).
For each spot, the local median background was sub-
tracted from the median foreground signal. A spot was
considered as positive (i) when it contained more than 55
% of foreground pixels above the background level + 1
standard deviation (STD) and (ii) less than 3 % of fore-
ground pixels saturated, (iii) when the linear regression
between the population of foreground pixels in the two
channels computed using the least-squares method was
above 0.5, and (iv) when the median of the pixel intensi-
ties at each wavelength with the median background pixel
intensity at each wavelength subtracted was above 500. A
positive feature was rated as relevant when the mean fore-
ground intensity was above the mean foreground signal
calculated from all negative control spots in at least one
channel. Log2 ratio independency from signal intensity in
both colour channels was assessed by displaying M-A
plots (Log2 ratio = f(Log2 (median signal intensity at 532
nm × median intensity at 635 nm)/2). To compensate for
dye bias, fluorescence data were subjected to a ratio-
based, global normalisation considering the median
intensity ratios of housekeeping genes. Genes detected in
less than 2/3 of the arrays or exhibiting absolute Log2
ratios < 1 were filtered out. Clustering and graphical anal-
ysis of the remaining gene expression data were per-
formed using the Acuity 4.0 software (Molecular Devices).
Microarray data were in compliance with the standards
proposed by the Microarray Gene Expression Data Society
[62], and were deposited in the ArrayExpress public repos-
itory [63].
Single color microarray
Transcriptome analysis were carried out using the Gene-
Chip HG-U133A 2.0 (Affymetrix, Santa Clara, CA, USA).
Sample labeling, hybridisation and staining were per-
formed at the Institut de Génétique et de Biologie Molécu-
laire et Cellulaire (IGBMC, Strasbourg, France) according
to the eukaryotic target preparation protocol in the
Affymetrix technical manual for Genechip expression
analysis [see Additional file 5]. Briefly, 200 ng of purified
poly(A+) RNA were linearly amplified to generate biotin-
labeled cRNA. Upon fragmentation, labeled cRNA were
hybridised for 16 h at 45°C according to the manufac-
turer's protocol. The hybridised arrays were washed and
stained with streptavidin-phycoerythrin (Invitrogen), and
signal was amplified with biotinylated anti-streptavidin
antibodies (Sigma, Bornem, Belgium) using a Genechip
fluidics station 400 (Affymetrix) according to the manu-
facturer's protocol. The arrays were scanned using a Gene-
chip scanner 3000 (Affymetrix) at a resolution of 1.56 µm.
The fluorescent intensity of each probe was quantified
using the Microarray Analysis Suite version 5.0 (MAS 5.0)
software (Affymetrix) according to manufacturer's instruc-
tions. The expression level of a single mRNA, defined as
the signal, was determined by the MAS 5.0 software which
uses a weighted average fluorescence intensity difference
obtained among the 11 probe pairs that interrogate the
expression of each individual gene. This software also
makes a detection call (present [P], marginal [M], or
absent [A]) for each gene or probe set, based on the con-
sistency of the performance of the individual probe pairs,
the hybridization above background, and the signal-to-
noise ratio. Data analysis was performed using default
parameters (Tau = 0.015).
Significance analysis of microarray data
The significance level achieved with Actichip microarrays
was evaluated by analysing the Log2 ratios from replicated
experiments using the Significance Analysis of Microar-
rays algorithm (SAM; [31]) in Microsoft Excel (addin vs
2.21). SAM uses a modified t-test to determine for each
gene represented on an array the relative difference in
gene expression d(i), taking into account both the abso-
lute level of expression as well as the standard deviation of
the replicates. SAM then estimates the expected relative
difference in expression de(i) for each gene by analysing
permutations of the measurements. On a plot of de(i) vs.
d(i), genes identified simply by chance are aligned on the
d(i) = de(i) line whereas the genes potentially significant
are represented by points displaced from this line by a dis-
tance greater than a threshold ∆. SAM also gives access to
the percentage of genes found to be significant by chance,
the false discovery rate (FDR).
Actin probe specificity
PCR primer design
PCR primers (18-mer) were designed for the specific
amplification of the six actin genes; actin, alpha 1, skeletal
muscle (ACTA1, NM_001100), actin, alpha 2, smooth
muscle, aorta (ACTA2, NM_001613), actin, beta (ACTB,
NM_001101), actin, alpha, cardiac muscle 1 (ACTC1,BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
Page 13 of 16
(page number not for citation purposes)
NM_005159), actin, gamma 1 (ACTG1, NM_001614),
actin, gamma 2, smooth muscle, enteric (ACTG2,
NM_001615). For all isoforms except ACTA1, the forward
primer was designed in a conserved region whereas the
different reverse primers were specific for the respective
actins [see Additional file 6]. All primers were verified by
using the BLASTN program.
PCR
The PCR reaction was performed using as template cDNA
generated from poly(A)RNA extracted from Hela cells.
Reaction mixtures were prepared by using 10× Ex Taq reac-
tion buffer and 2.5 U of Ex Taq polymerase (Takara Bio-
medicals, Otsu, Shiga, Japan) in accordance with
manufacturer's recommendations in a total volume of 50
µl or 100 µl. Thermal cycling was carried out using a
Robotcycler Gradient 96 (Stratagene, La Jolla, CA, USA)
with an initial denaturation step of 94°C for 4 min, fol-
lowed by 30 cycles of denaturation at 94°C for 30 s, an
annealing step at 58°C for 30 s, and an elongation step at
72°C for 30 s. Cycling was completed by a final elonga-
tion step of 72°C for 10 min. The presence and size of the
amplification products were determined by agarose (1%)
gel electrophoresis of the reaction product.
Labeling and Hybridisation
Specific PCR products were labeled chemically using the
ULYSIS labeling kit (Invitrogen) and Alexa Fluor 546 and
647 dyes according to the manufacturer's protocol. The
labeled DNA was purified with Qiagen QIAquick PCR
Purification kit, and was than recovered by ethanol pre-
cipitation, followed by resuspension in DIG Easy Hyb
hybridization solution (Roche Diagnostics, Mannheim,
Germany) at a concentration of 12.5 µg/ml. Hybridisa-
tions to Actichip microarrays were carried out for 16 h at
42°C as described previously using 20 µl of amplified and
labeled DNA solution and a 22×25 mm LifterSlip. After
incubation, microarrays were washed and scanned as
described previously.
Actichip sensitivity and detection limit
Preparation of spiked RNA samples
Spike poly(A+) RNAs were synthetised from the Arabidop-
sis thaliana spiking control cRNA vector set originally
developed at the Institute for Genomic Research (TIGR,
Rockville, MD, USA) by HindIII-SacI directional cloning
of PCR fragments corresponding to ten selected A. thaliana
genes into the pSP64 poly(A) vector (Promega, Madison,
WI, USA) [30]. Seven of these plasmids were linearised by
EcoRI digestion, the restriction site being positioned
immediately after the poly(A) tail sequence. One µg of
each linearised plasmid was used as template for the in
vitro synthesis of sense transcripts using the MEGAscript
High Yield Transcription kit (Ambion). Following DNA-
seI treatment, the transcribed RNAs were purified by lith-
ium chloride precipitation and resuspended in 10 mM
Tris-HCl pH 7.5. The quality and quantity of the RNA
samples were assessed with a RNA Labchip (Agilent Bio-
technologies) and classical spectrophotometry. RNA solu-
tions were adjusted at a concentration of 3 µg/µl
corresponding to 106 spike copies/cell/µl (cpc/µl), and
were mixed to prepare seven 10× test samples, each con-
taining a full range of spike RNAs at concentration ranging
from 1 to 105 cpc [see Additional file 1]. Transcript copy
number calculations were made assuming that a cell con-
tains 1 pg poly(A) RNA corresponding to an average of
360,000 transcripts, and that 0.3 ng spike transcript corre-
sponds to 100 spike copies/cell. Care was taken to use
DEPC-treated water containing 1 µg/µl  E. coli tRNA
(Roche Diagnostics) to prevent the loss of spike RNAs at
low concentrations through adsorption on plastic sur-
faces. An eighth 10 × RNA sample was constructed con-
taining the seven RNA spikes at a concentration
corresponding to 103 cpc.
Dose response curves
Dose response curves were determined using a procedure
modified from Allemeersch et al. [41]. Briefly, the seven
test mixes containing the spike RNAs in well-defined con-
centration and expression ratio were used as template to
prepare the Alexa dye 647-labeled samples, whereas the
reference mix was used for the generation of the Alexa
fluor 555-labeled sample. Test and reference samples were
pooled in equimolar concentration to obtain seven
hybridisation mixtures that were incubated for 20 h at
42°C onto distinct Actichip microarrays. Slides were
washed and scanned as described previously.
Microarray platform comparison
Sets of common probes between the different microarray
platforms were established on the basis of sequence acces-
sion numbers and/or sequence comparison. In the first
approach, RefSeq or GenBank accession numbers from
Actinome sequences were compared to the accession
numbers present in the annotation files provided by the
UMCU for the Operon probe set and by Affymetrix for the
HG-U133 2.0 GeneChip. In the second approach,
sequences of the Actichip targets (GenBank mRNA
sequences) were compared to those provided by Affyme-
trix ("target sequence") and the UMCU (GenBank and
RefSeq mRNA sequences). For this sequence similarity
search, we used the BLASTN program and the calculation
of two parameters, a global percent identity (GID) and a
percent coverage (pCover). GID was defined as the ratio of
the number of identical residues to the total number of
residues in all Maximum Segment Pairs (MSPs) of the
query [see Additional file 7]. pCover corresponded to the
ratio of the number of identical residues to the number of
residues that were aligned between the two sequences. To
avoid false negative results, similarity searches were per-BMC Genomics 2007, 8:294 http://www.biomedcentral.com/1471-2164/8/294
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formed using permissive cutoffs of 95% and 70 % for GID
and pCover, respectively. All alignments were then
curated manually.
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rectangle corresponds to the target sequence used by Affymetrix to design 
the probe sets.
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Additional file 4
CADO4MI user manual.
Click here for file
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2164-8-294-S4.pdf]
Additional file 5
Experimental protocols for transcriptome analysis.
Click here for file
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Additional file 6
Primers used for PCR amplification of the actin isoforms.
Click here for file
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2164-8-294-S6.xls]
Additional file 7
GID and pCover parameters. Sequences of the Actichip targets (GenBank 
mRNA sequences) were compared to the sequences (GenBank and RefSeq 
mRNA sequences) provided by Affymetrix ("target sequence") and the 
genomics laboratory at the university medical center of Utrecht (UMCU, 
The Netherlands) relative to the Operon probe set. This comparison was 
performed through sequence alignment using the BLASTN program and 
calculation of two parameters, a global percent identity (GID) and a per-
cent coverage (pCover). GID corresponds to the percentage of global iden-
tity between the query sequence (Qseq; Affymetrix or Operon target 
sequence) and one sequence (SeqB; Actichip target sequence) in the 
BLAST output. GID is determined by considering all best scoring align-
ments (MSP) between QSeq and SeqB and is computed as the ratio of the 
total number of identical residues (TNAR) to the total number of residues 
(TNRM) in all these alignments. pCover refers to the percentage of 
sequence coverage between QSeq and SeqB in the BLAST output. The cov-
erage corresponds to the extended overlapping regions between QSeq and 
SeqB considering all the regions aligned between the two sequences. 
pCover is computed as the ratio of the sum of all identical residues (NAR) 
to the number of residues in coverage (NRC).
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